Calquence® (acalabrutinib) – New indication
November 21, 2019 - The FDA announced the approval of AstraZeneca’s Calquence (acalabrutinib), for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
Download PDF
